|Bid||59.00 x 500|
|Ask||63.40 x 100|
|Day's Range||61.09 - 62.75|
|52 Week Range||37.35 - 63.77|
|PE Ratio (TTM)||-24.23|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
In the first half of 2017, Neurocine Biosciences (NBIX) generated revenues of $6.3 billion and reported expenses on the cost of product sales of $61.0 million.
Neurocrine Biosciences Inc. shares rose 3% in premarket trade Thursday after the company said the Food and Drug Administration has approved a higher, 80 mg dose of its tardive dyskinesia drug. The 80 mg ...
Neurocrine Biosciences shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.
Of the 12 analysts tracking Bioverativ (BIVV), three recommend a “strong buy” for the stock, while one recommends a “buy,” and seven recommend a "hold."
Neurocrine Biosciences shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 82.
Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
On August 3, 2017, Neurocrine Biosciences, Inc. (NBIX) announced financial results for the second quarter of 2017. The company reported $6.3 million in revenue from the sale of INGREZZA®, which was officially launched on May 1, 2017 following its approval by the U.S. Food and Drug Administration (FDA) in April 2017. In support of this, during the conference call to discuss the quarterly results, management indicated that the pharmacies keep less than 1 week of INGREZZA® in inventory.
The San Diego-based company said it had a loss of 68 cents per share. The results fell short of Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for ...
Bayer Aktiengesellschaft (BAYRY) announced that it has enrolled the first patient in a phase III study ASTEROID which will evaluate vilaprisan in women suffering from uterine fibroids.
In April 2017, the FDA approved Neurocrine Biosciences’ (NBIX) Ingrezza (valbenazine) as the first drug for the treatment of tardive dyskinesia.